<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211860</url>
  </required_header>
  <id_info>
    <org_study_id>PK015</org_study_id>
    <nct_id>NCT01211860</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects</brief_title>
  <official_title>A Multiple-Dose Pharmacokinetic Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects With Elevated Fasting Triglyceride Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essentialis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Essentialis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Once a day oral administration with DCCR is the optimal dosing regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      POPULATION The population will consist of generally healthy subjects with elevated fasting
      triglyceride levels in the range of ≥ 150 mg/dL and ≤ 1500 mg/dL at the Screening Visit.

      Number of Subjects A total of 10 subjects will be enrolled in the study at 1 site in the USA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-state Pharmacokinetic profile of DCCR</measure>
    <time_frame>10 days</time_frame>
    <description>Mean concentration-time profile for diazoxide
Steady-state pharmacokinetic parameters of diazoxide (Cmax(ss), AUC0-inf(ss), and CL/F)
Terminal elimination half-life (t½) of diazoxide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration-Time profile of major metabolite</measure>
    <time_frame>10 days</time_frame>
    <description>Steady-state pharmacokinetic parameters (Cmax(ss) and AUC0-inf(ss)) of the major metabolite of diazoxide
Terminal elimination half-life (t½) of the major metabolite of diazoxide
Metabolite-to-parent ratios at steady-state in terms of Cmax(ss) and AUC0-inf(ss)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hypertriglyceridmia</condition>
  <arm_group>
    <arm_group_label>DCCR Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCCR Treatment 290 mg diazoxide choline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide Choline Controlled-Release Tablet</intervention_name>
    <description>DCCR 290 mg once a day for 10 days</description>
    <arm_group_label>DCCR Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Basic requirements

          1. Healthy male and female subjects 18 to 75 years of age, inclusive at the time of
             dosing

          2. Body mass index (BMI) between 22 and 35 kg/m2

             Specific laboratory test results

          3. Fasting triglyceride ≥ 150 mg/dL and ≤ 1500 mg/dL

          4. Fasting glucose ≤ 110 mg/dL

          5. HbA1c ≤ 6.0 %

        Exclusion Criteria:

        Medications: recent, current, anticipated

          1. Thyroid hormones or preparations within 1 month prior to Screening Visit (except in
             subjects on stable dose of replacement therapy for at least 1 month)

          2. Thiazide diuretics within 2 weeks prior to Screening Visit

             History of allergic reaction or significant intolerance to:

          3. Diazoxide

          4. Thiazides

          5. Sulfonamides

             Lifestyle changes

          6. Subjects intending to change exercise habits, and/or quit smoking

             Specific diagnoses, medical conditions and history

          7. Known type I or III hyperlipidemia

          8. Known type 1 DM

          9. Known type 2 DM

         10. Any other clinically significant endocrine, cardiovascular, pulmonary, neurological,
             psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological
             disease interfering with the assessments of the investigational drug, according to the
             Investigator

             Specific laboratory test results

         11. Any relevant biochemical abnormality interfering with the assessments of the
             investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan K Copa, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research - Fargo, ND</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DCCR</keyword>
  <keyword>Diazoxide Chonline Controlled-Release Tablet = DCCR</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

